The Australian contribution to the literature on atypical antipsychotic drugs: A bibliometric study

Francisco López-Muñoz, David Castle, Winston Shen, Raquel Moreno, Lorena Huelves, Miguel Pérez-Nieto, Concha Noriega, Gabriel Rubio, Juan Molina, Cecilio Álamo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: We performed a bibliometric study on scientific publications on atypical antipsychotic drugs (AADs) from Australia. Methods: Using the EMBASE and MEDLINE databases, we chose those documents produced in Australia between 1993 and 2011, whose title included the descriptors atypic* (atypical*), antipsychotic*, second-generation antipsychotic*, clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone and blonanserin. We applied bibliometric indicators of production as well as dispersion. Results: We identified 438 relevant publications. The most widely studied AADs were clozapine (162 documents), olanzapine (103), risperidone (77) and quetiapine (42). There was a lack of exponential growth in publications over time, indicated by non-fulfilment of Price's Law (correlation coefficient r=0.9195 after exponential adjustment vs. r=0.9253 after linear adjustment). Publications appeared in 148 different journals, with four of the top nine journals having an impact factor greater than 3; 84 of the articles appeared in the Australian and New Zealand Journal of Psychiatry. Conclusion: Despite Australian publications on AADs appearing in reasonably high impact journals, most were confined to a single Australian psychiatry journal and overall publications did not show exponential growth over the period studied. This might reflect, inter alia, the relative paucity of medication trials being performed in Australia.

Original languageEnglish
Pages (from-to)343-345
Number of pages3
JournalAustralasian Psychiatry
Volume21
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Bibliometrics
Antipsychotic Agents
Publications
olanzapine
Social Adjustment
Risperidone
Clozapine
Psychiatry
Journal Impact Factor
Growth
New Zealand
MEDLINE
Databases

Keywords

  • Atypical antipsychotics
  • Australia
  • Bibliometry
  • Bipolar disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

López-Muñoz, F., Castle, D., Shen, W., Moreno, R., Huelves, L., Pérez-Nieto, M., ... Álamo, C. (2013). The Australian contribution to the literature on atypical antipsychotic drugs: A bibliometric study. Australasian Psychiatry, 21(4), 343-345. https://doi.org/10.1177/1039856213492352

The Australian contribution to the literature on atypical antipsychotic drugs : A bibliometric study. / López-Muñoz, Francisco; Castle, David; Shen, Winston; Moreno, Raquel; Huelves, Lorena; Pérez-Nieto, Miguel; Noriega, Concha; Rubio, Gabriel; Molina, Juan; Álamo, Cecilio.

In: Australasian Psychiatry, Vol. 21, No. 4, 08.2013, p. 343-345.

Research output: Contribution to journalArticle

López-Muñoz, F, Castle, D, Shen, W, Moreno, R, Huelves, L, Pérez-Nieto, M, Noriega, C, Rubio, G, Molina, J & Álamo, C 2013, 'The Australian contribution to the literature on atypical antipsychotic drugs: A bibliometric study', Australasian Psychiatry, vol. 21, no. 4, pp. 343-345. https://doi.org/10.1177/1039856213492352
López-Muñoz, Francisco ; Castle, David ; Shen, Winston ; Moreno, Raquel ; Huelves, Lorena ; Pérez-Nieto, Miguel ; Noriega, Concha ; Rubio, Gabriel ; Molina, Juan ; Álamo, Cecilio. / The Australian contribution to the literature on atypical antipsychotic drugs : A bibliometric study. In: Australasian Psychiatry. 2013 ; Vol. 21, No. 4. pp. 343-345.
@article{f69d347065c0438096eb423508760928,
title = "The Australian contribution to the literature on atypical antipsychotic drugs: A bibliometric study",
abstract = "Objective: We performed a bibliometric study on scientific publications on atypical antipsychotic drugs (AADs) from Australia. Methods: Using the EMBASE and MEDLINE databases, we chose those documents produced in Australia between 1993 and 2011, whose title included the descriptors atypic* (atypical*), antipsychotic*, second-generation antipsychotic*, clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone and blonanserin. We applied bibliometric indicators of production as well as dispersion. Results: We identified 438 relevant publications. The most widely studied AADs were clozapine (162 documents), olanzapine (103), risperidone (77) and quetiapine (42). There was a lack of exponential growth in publications over time, indicated by non-fulfilment of Price's Law (correlation coefficient r=0.9195 after exponential adjustment vs. r=0.9253 after linear adjustment). Publications appeared in 148 different journals, with four of the top nine journals having an impact factor greater than 3; 84 of the articles appeared in the Australian and New Zealand Journal of Psychiatry. Conclusion: Despite Australian publications on AADs appearing in reasonably high impact journals, most were confined to a single Australian psychiatry journal and overall publications did not show exponential growth over the period studied. This might reflect, inter alia, the relative paucity of medication trials being performed in Australia.",
keywords = "Atypical antipsychotics, Australia, Bibliometry, Bipolar disorder, Schizophrenia",
author = "Francisco L{\'o}pez-Mu{\~n}oz and David Castle and Winston Shen and Raquel Moreno and Lorena Huelves and Miguel P{\'e}rez-Nieto and Concha Noriega and Gabriel Rubio and Juan Molina and Cecilio {\'A}lamo",
year = "2013",
month = "8",
doi = "10.1177/1039856213492352",
language = "English",
volume = "21",
pages = "343--345",
journal = "Australasian Psychiatry",
issn = "1039-8562",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The Australian contribution to the literature on atypical antipsychotic drugs

T2 - A bibliometric study

AU - López-Muñoz, Francisco

AU - Castle, David

AU - Shen, Winston

AU - Moreno, Raquel

AU - Huelves, Lorena

AU - Pérez-Nieto, Miguel

AU - Noriega, Concha

AU - Rubio, Gabriel

AU - Molina, Juan

AU - Álamo, Cecilio

PY - 2013/8

Y1 - 2013/8

N2 - Objective: We performed a bibliometric study on scientific publications on atypical antipsychotic drugs (AADs) from Australia. Methods: Using the EMBASE and MEDLINE databases, we chose those documents produced in Australia between 1993 and 2011, whose title included the descriptors atypic* (atypical*), antipsychotic*, second-generation antipsychotic*, clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone and blonanserin. We applied bibliometric indicators of production as well as dispersion. Results: We identified 438 relevant publications. The most widely studied AADs were clozapine (162 documents), olanzapine (103), risperidone (77) and quetiapine (42). There was a lack of exponential growth in publications over time, indicated by non-fulfilment of Price's Law (correlation coefficient r=0.9195 after exponential adjustment vs. r=0.9253 after linear adjustment). Publications appeared in 148 different journals, with four of the top nine journals having an impact factor greater than 3; 84 of the articles appeared in the Australian and New Zealand Journal of Psychiatry. Conclusion: Despite Australian publications on AADs appearing in reasonably high impact journals, most were confined to a single Australian psychiatry journal and overall publications did not show exponential growth over the period studied. This might reflect, inter alia, the relative paucity of medication trials being performed in Australia.

AB - Objective: We performed a bibliometric study on scientific publications on atypical antipsychotic drugs (AADs) from Australia. Methods: Using the EMBASE and MEDLINE databases, we chose those documents produced in Australia between 1993 and 2011, whose title included the descriptors atypic* (atypical*), antipsychotic*, second-generation antipsychotic*, clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone and blonanserin. We applied bibliometric indicators of production as well as dispersion. Results: We identified 438 relevant publications. The most widely studied AADs were clozapine (162 documents), olanzapine (103), risperidone (77) and quetiapine (42). There was a lack of exponential growth in publications over time, indicated by non-fulfilment of Price's Law (correlation coefficient r=0.9195 after exponential adjustment vs. r=0.9253 after linear adjustment). Publications appeared in 148 different journals, with four of the top nine journals having an impact factor greater than 3; 84 of the articles appeared in the Australian and New Zealand Journal of Psychiatry. Conclusion: Despite Australian publications on AADs appearing in reasonably high impact journals, most were confined to a single Australian psychiatry journal and overall publications did not show exponential growth over the period studied. This might reflect, inter alia, the relative paucity of medication trials being performed in Australia.

KW - Atypical antipsychotics

KW - Australia

KW - Bibliometry

KW - Bipolar disorder

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84889039612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889039612&partnerID=8YFLogxK

U2 - 10.1177/1039856213492352

DO - 10.1177/1039856213492352

M3 - Article

C2 - 23804115

AN - SCOPUS:84889039612

VL - 21

SP - 343

EP - 345

JO - Australasian Psychiatry

JF - Australasian Psychiatry

SN - 1039-8562

IS - 4

ER -